Professional
Added to YB: 2024-09-12
Pitch date: 2024-06-30
CRSP [bullish]
CRISPR Therapeutics AG
+4.92%
current return
Author Info
No bio for this author
Company Info
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
Market Cap
$5.3B
Pitch Price
$54.02
Price Target
N/A
Dividend
N/A
EV/EBITDA
-8.30
P/E
-9.91
EV/Sales
92.31
Sector
Biotechnology
Category
value
Loomis Sayles Global Growth Fund Portfolio Holding: CRISPR Therapeutics AG
CRSP: Pioneering gene editing co w/ Nobel-winning tech. Casgevy approved in multiple countries for SCD/TDT. 25+ treatment centers activated. Pipeline includes CAR-T for cancer/autoimmune & liver disease therapies. $2.1B cash, 3+ years runway. 40%+ potential op margins. Undervalued vs curative therapy potential & structural advantages.
Read full article (3 min)